Parmax Pharma Fair Value
Parmax Pharma fair value. Parmax Pharma (PARMAX) average fair value is ₹241.61 across 1 valuation models — Price-to-Sales Valuation, vs a current market price of ₹137.75 (+75.4%), fair value range ₹241.61–₹241.61. Explore Parmax Pharma intrinsic price to estimate fundamental worth using multiple valuation models.
Fair Value Analysis Export
PARMAX Fair Value vs Current Price — Valuation Summary
PARMAX average fair value, fair value range, price gap and valuation status across 1 models: Price-to-Sales Valuation. For live price and a broader fundamental view, visit PARMAX share price.
Price-to-Sales Valuation
PARMAX Fair Value Analysis — Data Sources & Coverage
Parmax Pharma financial data sources, valuation methods applied and sector benchmarks used. Check PARMAX company valuation to track the company's total market size over time.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
PARMAX vs Healthcare Sector Peers — P/E, P/B & Market Cap
Parmax Pharma P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Emcure Pharmaceuticals | EMCURE | 35.85 | 7.38 | ₹37,156 |
| Divis Laboratories | DIVISLAB | 84.36 | 14.72 | ₹244,125 |
| Aurobindo Pharma | AUROPHARMA | 25.97 | 2.54 | ₹96,479 |
| Syngene International | SYNGENE | 65.37 | 2.98 | ₹14,538 |
| Sat Kartar Life | SATKARTAR | 16.56 | 4.14 | ₹307 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.